期刊
PHARMACEUTICALS
卷 14, 期 1, 页码 -出版社
MDPI
DOI: 10.3390/ph14010025
关键词
angiogenesis; anastomosis; vascular development; derazantinib; FGFR-signalling; VEGFR-signalling; infigratinib; vatalanib; zebrafish
资金
- Kantons Basel-Stadt and Basel-Land
- Swiss National Science Foundation
Derazantinib (DZB), an inhibitor of fibroblast growth factor receptors and vascular endothelial growth factor receptors, may have a potential dual role as an anti-angiogenic treatment. The study demonstrated in a zebrafish embryo model that DZB interferes with various angiogenic processes linked to FGF and VEGF signaling.
Angiogenesis is a fundamental developmental process and a hallmark of cancer progression. Receptor tyrosine kinases (RTK) are targets for cancer therapy which may include their action as anti-angiogenic agents. Derazantinib (DZB) is an inhibitor of the fibroblast growth factor receptors (FGFRs) 1-3 as well as other kinase targets including vascular endothelial growth factor receptor 2 (VEGFR2), colony stimulating factor-1 receptor (CSF1R) and platelet-derived growth factor beta receptor (PDGFRbeta). This study aimed to investigate the effect of DZB on blood vessel morphogenesis and to compare its activity to known specific FGFR and VEGFR inhibitors. For this purpose, we used the developing vasculature in the zebrafish embryo as a model system for angiogenesis in vivo. We show that DZB interferes with multiple angiogenic processes that are linked to FGF and VEGF signalling, revealing a potential dual role for DZB as a potent anti-angiogenic treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据